Exercise for Improving Radiotherapy Efficacy in Rectal Cancer

This study will take place at Castle Hill Hospital, where the participants' usual care will be given. The study will also recruit at this site. Patients, who have been diagnosed with locally advanced rectal cancer (LARC) short-course radiotherapy (NART) will be pre-screened for any obvious exclusions with those that are potentially eligible approached by their clinical oncologist to discuss participation in these studies. If the patient is agreeable, further contact will be made by a member of the research team for further discussion. The aim is to include about 30 participants in this study. The participant information sheet will be provided and any uncertainties about the study raised by the potential participant will be addressed. The potential participant will be given sufficient time, up to a week, to consider their participation in the study, as typically, there is on average a 31-day period between decision to treat and start of neoadjuvant oncological treatment. After all questions are answered and provided the participant is willing to take part in the study, they will be asked to sign the consent form to confirm participation.

Once a participant agrees to taking part, their medical history, and investigations (performed as part of routine clinical care) will be reviewed. Each participant's data from investigational phase for rectal cancer up to short-course NART completion and re-assessment will be collected. Data on age, gender, stage of rectal cancer, and any comorbidities will be collected from medical notes. Participants will then be invited for a baseline assessment at Castle Hill Hospital in a designated risk assessed rehabilitation gym.

In this baseline assessment, further personal details will be taken from the patient, including height and weight measurements to calculate Body Mass Index (BMI), other descriptive information such as ethnicity will also be taken. The Patient Reported Outcome Measures (PROMs) will be completed either independently by participant or with the help of a member of the research team if required by participant. Some of the questionnaires, such as the European Organisation for Research and Treatment of Cancer EORTC-QLQ-CR29 and Functional Assessment of Cancer Therapy - Colorectal (FACT-C), contained in this study contain some questions that may be perceived to be intrusive. They however are validated questionnaires that has previously been used in numerous rectal cancer research studies. To mitigate embarrassment, participants will be forewarned about the contents of these questionnaires and potential to cause embarrassment. Participants will be reminded that their response will be anonymised. Questions relating to stoma and sex life are presented much later in the questionnaires where rapport may have already been established. Participants will be encouraged to consult with their oncologist if the questionnaires prompt any treatment related problems they may be experiencing.

Participants will also on this day, be provided an accelerometer to wear on 7 randomly selected days at different timeframes of the study. Finally on this day an average of three resting heart rates will be taken. The value of the average of the resting hear rates will be used in calculating a heart rate reserve (HRR) of 60%, 70% and 80%. Using the formula (HRmax-RHR) × exercise intensity (60-80%) + RHR, where HRmax is 220-Age as found to be effective. This will form one of the main bases for exercise intensity, to ensure individualisation of the supervised vigorous intensity interval training sessions.

The supervised hospital-based exercise will be delivered over a 7-week period. This is because short-course neoadjuvant radiotherapy lasts 5-days in a week. This design allows for a 2-week pre-neoadjuvant oncological and a 4-week post-neoadjuvant oncological treatment. Exercise will involve an hour long, twice weekly vigorous intensity aerobic interval exercise and twice weekly supported at-home resistance training, from 2 weeks prior to the start of oncological treatment to the beginning of NART. In the week of NART, participants will receive 5 consecutive days of vigorous intensity aerobic interval training 1.5 hours before radiotherapy only. Following this week of short-course NART, participants will return to receiving twice weekly vigorous intensity aerobic interval exercise and twice weekly supported at-home resistance training, for four weeks. Vigorous intensity aerobic interval exercise will be performed at 70-80% of heart rate reserve (HRR).

The first supervised vigorous intensity interval training class will feature an induction and orientation into the gym, facilities nearby, like a toilet and safety checks during exercise classes. Participants will be encouraged to be proactive in expressive their bodies response to the exercises and to seek help promptly if required. Participants will also on this day, be provided an accelerometer to wear on the days for unsupervised resistance training.

These supervised vigorous intensity interval training sessions will be delivered on an individual basis, lasting up to 60-minutes, performed on a cycle ergometer, and supervised by at least one trained exercise practitioner or a physiotherapist. The sessions will include a 5-minute warm up and 5-minute cool down. The interval phase will include up to 6 bouts of vigorous intensity interval training alternating between 5minutes of pedalling at up to 70-80% HRR and 2.5 minutes active rest, pedalling with no resistance at less than 60% HRR.

At the end of the exercise phase of the studies their will be a post-exercise assessment on the next working day of exercise completion, where all the information taken in the baseline assessment will be collected for comparison. Participants will not be seen again until their post-surgery phase, which will be 6 months from the start of NART . At this stage, information about Pathological complete response(PCR) or Radiological complete response (RCR) and tumour regression (TR) will be collected.

There will also be a semi-structured interview to explore participant satisfaction of the trial and acceptability of the exercises. Notes will be taken during the interview. The interview data will be coded and analysed via reflexive thematic analysis using the NVivo qualitative analysis software. People approached about the study in clinic who choose not to participant will be encouraged to discuss why they chose not to participate in a short survey with questions adapted from the study by Dwyer and colleagues. Information from this survey may be instrumental in adapting the study design appropriately to better serve this patient group.

There may be one additional research visit if sufficient data cannot be obtained from the medical notes. This will be face to face or via telephone, depending on participant preference and every attempt will be made to coordinate this with participants oncological appointment.

The total period of participation in the study for each patient will be at most 7 months, this is with a gap between completion of exercise and 6-month review from start of neoadjuvant oncological treatment. All research activities is planned to be completed within 18 months of receiving approval from the Research Ethics Committee(REC).

This study design will allow us to determine the proportion of people in our region with LARC who are willing to engage in structured outpatient exercise before, during and after short-course NART. There are not sufficient safety data in United Kingdom (UK) based subjects at present to justify incorporating exercise in all stages of the rectal cancer care pathway according to the current guidelines. Additionally, this study will also provide safety data by determining the proportion of LARC patients who are able to complete supervised vigorous Intensity Interval training and unsupervised training at home. The exploratory goals of these studies may provide indicative data on the impact of vigorous intensity training on quality of life and short-course NART efficacy.

Data generated from the study will be aggregated, anonymised, and used for publication in scientific journals and presented in abstract form at scientific meetings. All patient identifiable information will be always kept confidential. Anonymised data may be available to the scientific community following the end of the study. Data will be stored confidentially at the university of Hull for a maximum of 5 years for future research use if needed before it is fully destroyed. The management of the study will be overseen by the chief investigator. Regular meetings will be held by the chief investigator and members of the research team involved in the study to ensure all the correct steps are being taken and to address any issues that could exist.